Various studies have shown that organic cation transporter-1 (OCT1) is involved in the uptake of potent cationic anti-tumor drugs, such as Cisplatin, anthracyclines, and sorafenib and its activity is dysregulated in many cancers such as colon and liver cancer [322–325]. Here, SLC22A1 is linked to cancer.